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Abstract
Background: This report discusses a case of unsuccessful treatment with recombinant factor VIIa
(rFVIIa) in off-label use. The need for international guidelines concerning the off-label use of rFVIIa
is outlined as well as the need for methods to control the efficacy of rFVIIa objectively.
Case presentation: 54 year old male with severe polymicrobial sepsis due to a perforated
diverticulitis of the sigmoid colon and consecutive overt disseminated intravascular coagulation. He
suffered severe intraabdominal bleeding after abdominal surgery despite conventional haemostatic
support. Repeated applications of factor VIIa temporarily improved coagulation essays but did not
stop clinical bleeding. The patient died in multiorgan failure due to septic and haemorrhagic shock.
Conclusion: Off-label use of rFVIIa could result in more side effects than could be expected from
literature because of a publication bias. However for most off-label applications large prospective,
randomised and controlled trials to confirm the positive findings are missing. For the future, not
only guidelines concerning the off-label use of rFVIIa are urgently needed but also guidelines for
monitoring the efficacy of rFVIIa.
Background
Recombinant factor VIIa (rFVIIa) has been used since
1988 to control bleeding in haemophilia A and B patients
with inhibitors against factor VIII and IX [1-3]. A standard
dose of 90 μg/kg body weight in repeated administrations
was defined as being efficacious. This is the only interna-
tionally licensed indication for rFVIIa. However, the agent
became famous for being successful in other critical situa-
tions, where uncontrolled bleeding persisted despite mas-
sive conventional haemostatic support. Successful
treatments were reported in patients with inherited factor
VII deficiency or with thrombocytopathy, upper gastroin-
testinal bleeding, after surgery or trauma, in bleeding
patients treated with anticoagulants (warfarin, tirofiban)
and in patients with disseminated intravascular coagula-
tion (DIC). These indications are known in the literature
as off-label use and are based on data published as case
reports or observational studies, almost always demon-
Published: 26 April 2007
BMC Infectious Diseases 2007, 7:34 doi:10.1186/1471-2334-7-34
Received: 25 October 2006
Accepted: 26 April 2007
This article is available from: http://www.biomedcentral.com/1471-2334/7/34
© 2007 Conen et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 6
(page number not for citation purposes)
BMC Infectious Diseases 2007, 7:34 http://www.biomedcentral.com/1471-2334/7/34strating a beneficial effect [4]. Off-label use is described in
national guidelines [5,6], which are worked out mostly by
haematologists and specialists in intensive care medicine.
Only a few prospective randomised trials exist in non-hae-
mophilic patients examining the indication, dose regi-
men, efficacy and safety of the treatment with rFVIIa [7-
10]. In these trials a positive effect of rFVIIa was shown in
patients with intracerebral haemorrhage (limited growth
of the haematoma and reduced mortality) [7] and in
patients suffering a blunt trauma (reduced transfusion
requirements) [8]. Only a trend toward a better outcome
was shown in patients with a penetrating trauma receiving
rFVIIa. On the other hand, no positive effect of rFVIIa was
documented in patients after haematopoietic stem cell
transplantation (HSCT) suffering a bleeding complication
from any cause [9], or in patients undergoing an ortho-
topic liver transplantation in end-stage liver disease [10].
rFVIIa acts at sites where the endothelium is damaged and
tissue factor is released, implying a local mode of action.
rFVIIa forms a complex with the tissue factor and then
activates factor X and platelets, resulting in the local gen-
eration of thrombin and consecutively in the formation of
a stable fibrin clot [11].
We describe a severely ill patient suffering from overt DIC,
who received rFVIIa because of uncontrolled intraabdom-
inal bleeding after abdominal surgery. The patient died in
septic and haemorrhagic shock despite adequate treat-
ment and use of rFVIIa (Novoseven®).
Case presentation
A 54 year old man presented in the emergency depart-
ment of our hospital with a three weeks history of fever,
shivering, abdominal discomfort and watery, unbloody
diarrhoea. The patient's medical history was otherwise
remarkable for a metabolic syndrome with arterial hyper-
tension, diabetes mellitus type 2 and obesity. His regular
medication consisted of metformin and enalapril/hydro-
chlorothiazide. The clinical examination confirmed a bad
general health condition with intermittent fever up to
40°C and shivering. He was hypotensive (85/55 mmHg),
had a normal pulse rate and was tachypnoic (20 breaths/
min.). The abdomen was distended; showed normal
bowel sounds and rebound tenderness – consistent with a
diffuse peritonism. Furthermore the clinical examination
was unremarkable. Laboratory profile was consistent with
systemic inflammation, acute renal failure and hepatopa-
thy. Platelets were low with 41 G/l (normal range 150–
450 G/l). Lactate and coagulation parameters were within
normal limits. Antibodies for hepatitis A, B and C were
negative. Urine analysis was unremarkable. The abdomi-
nal computerized tomography (CT scan) showed a big ret-
roperitoneal abscess provoked by a diverticulitis of the
sigmoid colon, as well as air in the portal vein system and
in the inferior mesenteric vein (pylephlebitis). Ascites and
hepatosplenomegaly were present (figure 1, 2, 3).
Sepsis due to the described intraabdominal focus was
diagnosed and a broad-spectrum antibiotic treatment
with intravenous piperacillin/tazobactam and amikacin
was started. After administration of fluids blood pressure
stabilized. Cultures of ascites fluid were positive for Kleb-
siella pneumoniae, Escherichia coli and Candida albicans.
In blood cultures Escherichia coli, Klebsiella oxytoca and
Bacteroides fragilis could be isolated without resistances
against piperacillin/tazobactam. In order to treat the
intraabdominal growth of Candida albicans high-dose
Air in the inferior mesenteric veinF gure 2
Air in the inferior mesenteric vein.
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second hospital day to evacuate the retroperitoneal
abscess (Hartmann's operation: sigma resection, generat-
ing a colostomy with the proximal end of the descending
colon and a blind rectal pouch with the proximal end of
the distal segment). Because of anuria haemofiltration
was started after surgery. During haemofiltration low
doses of unfractionated heparin were administered to
keep the filter patent.
One week later – on day 9 of hospitalisation – secretions
from abdominal drainages became bloody and cloudy
with an amount of 2000 ml/day. The coagulation profile
at this time was: thrombocytes 52 G/l, international nor-
malized ratio (INR) 1.3 (normal range <1.3), pro-
thrombin time (PT) 14.5 s (normal range <11 s), activated
partial thromboplastin time (aPTT) 44 s (normal range
25–34 s), fibrinogen 3.2 g/l (normal range 1.7–4 g/l) and
factor VII 29% (normal range 70–120%). There was a pro-
gressive metabolic acidosis with lactate levels around 6 to
17 mmol/l (normal range <1.8 mmol/l). As the treatment
with metformin had been stopped at admission, when
lactate levels were within normal limits, the current pro-
gressive lactate acidosis was ascribed to ongoing sepsis.
With raising inflammatory markers, antibiotic therapy
was changed to meropenem and a second laparotomy was
performed. A putrid retroperitoneal haematoma was
removed. During surgery, diffuse intraabdominal bleed-
ing required extended surgical blood coagulation and the
substitution of 1 platelet (TC) and 6 packed red cell con-
centrates (RC), as well as 7 units of fresh frozen plasma
(FFP). At this time the patient received intraoperatively
one dose of rFVIIa (70 μg/kg). The coagulation profile at
this time was consistent with a DIC with platelets 62 G/l,
INR 1.4, PT 16 s, D-Dimers 3.22 μg/ml (normal range
<0.5 μg/ml), fibrinogen 1.2 g/l and aPTT 80 s. Because of
the sustained bleeding the abdomen was left open to pre-
vent intraabdominal compartment syndrome. Postopera-
tively high doses of vasoactive drugs had to be
administered to maintain circulation. Severe metabolic
acidosis (pH 6.9) with a lactate of 22 mmol/l was present
because haemofiltration had to be discontinued during
surgery. The bleeding remained uncontrolled despite fur-
ther substitution of 1 TC and 6 RC, 5 FFP, tranexamic acid
(Cyclokapron®), protamin hydrochloride (Protamin®)
and von Willebrand factor concentrate (Haemate®).
Therefore, a second dose of rFVIIa (70 μg/kg) was given.
Twelve hours after the second laparotomy – in the morn-
ing of day 10 – a third laparotomy was performed. Again,
a haematoma with diffuse retroperitoneal bleeding had to
be removed. Surgical haemostasis and retroperitoneal
cloth packing for tamponade were performed. The patient
received intraoperatively 4 EC, 6 FFP and 2 doses of rFVIIa
(each 70 μg/kg). After the surgery, the bleeding remained
uncontrolled despite the administration of 3 FFP every 8
hours, rFVIIa every 4 hours (35 μg/kg) and TC and RC as
needed (figure 4). The patient died 15 hours after the third
operation in multiorgan failure. No autopsy was per-
formed.
Discussion
We described a patient with severe polymicrobial sepsis
secondary to a perforated diverticulitis of the sigmoid
colon with pylephlebitis, who developed an overt DIC
and uncontrolled intraabdominal bleeding postopera-
tively. Despite massive transfusions and the substitution
of haemostatic agents including rFVIIa, bleeding persisted
and the patient died in septic and haemorrhagic shock 10
days after being hospitalised.
Many case reports describing clinical efficacy and safety of
rFVIIa in different acquired bleeding situations can be
found in literature [4]. Despite these positive experiences,
randomised and controlled trials are rare [7-10]. But those
trials would be crucial for developing international guide-
lines concerning the off-label use of rFVIIa. Questions as
"who should get rFVIIa at what time in what dose?" need
to be answered.
There are known factors negatively influencing the effi-
cacy of rFVIIa (e.g. hypothermia, acidosis, prolonged
preadministration prothrombin time or hyperfibrinoly-
sis) [12]. These factors should be corrected prior to the
administration of rFVIIa. Especially acidosis seems to
compromise the enzymatic actions in the coagulation cas-
cade. Meng et al [13] describe that a decrease in pH from
7.4 to 7.0 reduces the activity of rFVIIa by 90% in an in
vitro setting. However, the optimal time point of admin-
istration of rFVIIa is difficult and not well defined yet:
administering rFVIIa too early may decrease efficacy due
Air in the portal vein systemF gure 3
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and antifibrinolytics, but also due to initial acidosis; wait-
ing too long may worsen metabolic state, aggravate acido-
sis and therefore coagulopathy. In a retrospective analysis
by Clark et al [14], examining rFVIIa as a "last-ditch" in
patients with massive haemorrhage unresponsive to con-
ventional pharmacologic and surgical treatment and to
massive transfusions, high mortality rates (1-day and 7-
day mortality 40% and 70% respectively) were noted with
only 60% of the patients receiving rFVIIa responding at
least transiently with a cessation of bleeding. The authors
conclude that last-ditch rFVIIa therapy is ineffective in
patients who do not respond to extended conventional
treatment. Our patient received rFVIIa as a last ditch ther-
apy when overt DIC with prolonged PT (16 s) and ele-
vated D-Dimers (3.22 μg/ml) was already present and
massive transfusions were unsuccessful. He was in a severe
metabolic acidosis (pH 6.9 and lactate >20 mmol/l) at the
time of administration. All factors together – prolonged
preadministration prothrombin time, hyperfibrinolysis
and especially severe acidosis – might be causal for unre-
sponsiveness to rFVIIa, as might be the progressive liver
failure.
The use of rFVIIa in patients with DIC – where there is sys-
temic activation of coagulation with systemic exposure of
tissue factor [15] – could lead to more pronounced side
effects. But no controlled trials exist to confirm this hypo-
thesis. Case reports and case series show successful use of
rFVIIa in DIC [16-18]. Noteworthy is that no thromboem-
bolic complications occurred in those cases. However, a
publication bias can not be excluded. It is difficult to com-
pare the published cases with our patient concerning the
effectiveness of rFVIIa. First we state that doses of rFVIIa
administered were different, 90 μg/kg versus 70 μg/kg or
less in our patient; second, in the published cases there is
no information on the metabolic situation and worsened
action of rFVIIa by metabolic acidosis. However, in our
patient the metabolic situation with severe acidosis might
explain at least partially the lack of effect.
Ineffectiveness of rFVIIa has not been published very
often so far in case reports [19], but there are three rand-
omized controlled trials, in which rFVIIa did not show
any benefit compared to placebo [8-10]. In the latter two
cited studies different doses of rFVIIa were administered
(20, 40 or 80 μg/kg, respectively 40, 80 or 160 μg/kg). In
the literature no consensus exists about the appropriate
dosage of rFVIIa. Used dosages range from 15–160 μg/kg
in single or multiple administrations, making compari-
sons difficult.
Major side effects of rFVIIa are thromboembolic events
(myocardial infarction, cerebrovascular accidents, pulmo-
nary embolism, thrombosis in other arterial or venous
sites and clotted devices). Other, non thromboembolic
adverse events are rash, allergic reactions, lack of effect
and unspecific symptoms such as pain, nausea or vomit-
ing [20,21]. Sometimes it is difficult to relate the reported
event to rFVIIa, because some events occur days after the
Measured values of aPTT, platelets and arterial pH during the treatment with rFVIIaFigure 4
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bidities, offering a more probable explanation for a
thromboembolic event than rFVIIa.
Besides clinical responsiveness, the effect of rFVIIa should
be monitored with laboratory parameters, whereas appro-
priate tests are discussed controversially. Thromboelastog-
raphy would allow the evaluation of the effects of rFVIIa
on haemostasis [22,23]. This method consists of a viscoe-
lastic measurement of clotting time, clot formation time
and maximum clot firmness in whole blood, but it is not
routinely available in most hospitals. The conventional
measurement of the activity of factor VII or VIIa in plasma
after the administration of rFVIIa only proves the exist-
ence of factor VII and its successful administration, but it
does not predict any effect on haemostasis [11,22]. The
factor VII activity in our patient, measured with conven-
tional methods, was consistently >120% after the repeti-
tive administration of rFVIIa. This was reflected in a
transient shortening of aPTT- and INR-values (figure 4).
Despite this in vitro activity, factor VIIa was not clinically
effective in our patient. The only conclusion allowed by
the conventional measurement therefore is that the drug
was successfully administered intravenously. The objec-
tive parameters measured by thromboelastography would
have been helpful not only in controlling efficacy of
rFVIIa but also in dose finding decisions. For the future,
hence, not only guidelines concerning the off-label use of
rFVIIa are urgently needed but also guidelines for moni-
toring the efficacy of rFVIIa.
Conclusion
In many case reports, efficacy and safety of rFVIIa in the
off-label use are discussed. For most off-label applications
large prospective, randomised and controlled trials are
however missing, confirming the positive findings. Based
on such trials, international guidelines should be elabo-
rated, giving consent on how and when to administer
rFVIIa. The off-label use of rFVIIa could result in more side
effects than could be expected from the literature because
of a publication bias. On the other hand, it also implies
high costs, which nowadays are generally a major issue in
medicine. For the future, not only guidelines concerning
the off-label use of rFVIIa are urgently needed but also
guidelines for monitoring the efficacy of rFVIIa.
Key messages
• Guidelines for the off-label use of rFVIIa are required.
• Guidelines for monitoring the efficacy rFVIIa are
required.
• The efficacy of rFVIIa could be overestimated because of
a potential publication bias.
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